HRH3 and Alzheimer disease: In this study, we found that oral administration of LC1405 increased the levels of histamine and ACh in mouse brain (Figure 3C,D), which was in accordance with the hypothesis that H3R antagonists increased neurotransmitter levels involving ACh and histamine in the brain, thus counteracting AD deficits (Bitner et al., 2011).